Craft
GlycoMimetics

GlycoMimetics

Revenue

$1.2 M

FY, 2021

Market Capitalization

$173.3 M

2023-01-26

GlycoMimetics Summary

Company summary

Overview
GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.
Type
Public
Status
Active
Founded
2003
HQ
Rockville, MD, US | view all locations
Website
http://www.glycomimetics.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Brian Hahn

    Brian Hahn, Chief Financial Officer and Senior Vice President

  • Rachel K. King

    Rachel K. King, Director

    • Harout Semerjian

      Harout Semerjian, President and Chief Executive Officer

    • Helen Thackray

      Helen Thackray, Chief Medical Officer & Senior Vice President, Clinical Development

    LocationsView all

    1 location detected

    • Rockville, MD HQ

      United States

      9708 Medical Center Dr

    GlycoMimetics Financials

    Summary financials

    Net income (Q3, 2022)
    ($8.5M)
    Cash (Q3, 2022)
    $51.6M
    EBIT (Q3, 2022)
    ($8.8M)
    Enterprise value
    $122.9M

    Footer menu